Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD
3/18/2014 9:14:39 AM
TEL AVIV, Israel, March 18, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that, following the recent FDA acceptance of the Company's IND for MDX, the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD.
Help employers find you! Check out all the jobs and post your resume.
comments powered by